Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live
304 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
304
Total Reports
29
Deaths Reported
950.0%
Death Rate
Active Ingredients
Canine Adenovirus Type 2,Toronto A/26/61,LiveCanine Distemper,Vcp258,VectorCanine Parainfluenza Virus,D-008,LiveCanine Parvovirus,780916,Live
Administration Routes
SubcutaneousUnknown
Species Affected
Dog 304
Most Affected Breeds
Retriever - Labrador 24
Retriever - Golden 23
Chihuahua 18
Terrier - Yorkshire 16
Crossbred Canine/dog 13
Pit Bull 13
Shih Tzu 10
Dachshund (unspecified) 9
Poodle - Toy 9
Poodle - Miniature 9
Most Reported Reactions
Vomiting 101
Lethargy (see also Central nervous system depression in 'Neurological') 67
Diarrhoea 55
Injection site pain 35
Anorexia 26
Other abnormal test result NOS 26
Lethargy (see also Central nervous system depression in Neurological) 24
Neutrophilia 22
Leucocytosis NOS 21
Death 19
Seizure NOS 19
Fever 19
Outcome Breakdown
Outcome Unknown
122 (40.0%)
Recovered/Normal
116 (38.0%)
Ongoing
37 (12.1%)
Died
18 (5.9%)
Euthanized
12 (3.9%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.